SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

John Freidenrich

October 17, 2017 - SCI Communications

Earlier this month John Freidenrich passed away at age 80. He was a Stanford alumnus who had been involved with the university for more than 40 years, and along with his wife Jill, donated $25 million to open the Freidenrich Center for Translational Research at 800 Welch Road. Read more about John and his important contributions to Stanford here.

Staff Update from Brenda

October 6, 2017 - SCI Communications

Please join me in welcoming Pei-Jen Chang to the role of Associate Director, Clinical Research Operations supporting the Cancer Clinical Trial Office.

Pei-Jen started her career in the CCTO as a clinical research coordinator in 2010 after working as a Lead Oncology Clinical Research Coordinator for Kaiser Permanente. Pei-Jen was promoted into her current Clinical Research Manager role in 2012. With the help of the faculty she supports, Pei-Jen successfully integrated clinical research into the women’s health programs through deep collaboration and commitment to the mission.

Pei-Jen has tirelessly dedicated herself to improving operational processes in the Women’s Health clinical research program and the CCTO overall. A couple of examples include being an early adopter for streamlining financial management and maintaining active community engagement through development of a newsletter for Women’s Health which is distributed to community physicians in the Bay Area.

Please extend a warm welcome to Pei-Jen in her new role.

Brenda

HR Update: Open Positions and Referral Bonuses

October 5, 2017 - SCI Communications

We currently have the following openings at CCTO. If you know someone who would be a good fit for one of these positions, please send their resume to Jamie Pauley.

CRG Title Req #
Finance Research Administrator 3 73663
GI Clinical Research Coordinator 2 75202
RadOnc Clinical Research Coordinator 2 75283
Non-Clinical Cancer Clinical Research Business Associate Director 75382
Thoracic Assistant Clinical Research Coordinator
(6 Month Fixed-Term)
75850
ENT Clinical Research Coordinator 2 76098
Peds Clinical Research Coordinator Associate 76136
CCT Clinical Research Coordinator Associate 76196
BMT Clinical Research Coordinator Associate 76270
Radiology Clinical Research Coordinator Associate 76305
ENT Clinical Research Coordinator Associate 76306
Phase 1 Clinical Research Coordinator Associate 76307
Lymphoma Clinical Research Coordinator Associate 76458
Lymphoma Clinical Research Coordinator 2 76486
Hematology Clinical Research Coordinator Associate 76529

 

Stanford Cancer Institute Employee Referral Program
Help a friend and help CCTO find good employees! SCI is offering a referral bonus of up to $1000 if your candidate is hired into an open position in SCI/CCTO. If you and the candidate fit the eligibility criteria, ask them to apply online and list your name under source tracking: employee referral. Please fill out the referral form and send it along with the candidate’s resume to Marina Mendieta Romero. More requirements and details are available on the referral form. If you have any questions about the referral program please contact Marina.

What’s New at the IRB

October 4, 2017 - SCI Communications

Stay Informed: Don’t forget to check the IRB website’s “What’s New” section for important news. Recent updates include:

  • Requirements for Single IRB applications in eProtocol: Relying on a Single IRB (sIRB) and sIRB SOP
  • Short Form Consent Process (updated to reflect the witness does not have to speak the participant’s language)
  • Events and Information that Require Prompt Reporting to the IRB (updated with additional examples)

Check out the entire list of new updates on the IRB website.

New FDA Approved Drug for Breast Cancer

October 4, 2017 - SCI Communications

On September 28, 2017, The U.S. Food and Drug Administration approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy). Many thanks to the Breast Group for their hard work on BRS0044, a Phase 3 Eli Lilly trial that studied this drug. More information can be found on the FDA’s press release.

  • « Previous Page
  • 1
  • …
  • 160
  • 161
  • 162
  • 163
  • 164
  • …
  • 166
  • Next Page »

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • PRISM
  • PRMS
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube